• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Invest in Pfizer? Know That the Stock Is Not Volatile or That Risky

PFE reported Q1 earnings Tuesday and handily beat expectations.
By STEPHEN GUILFOYLE
maj 04, 2021 | 11:00 AM EDT
Stocks quotes in this article: PFE, BNTX

We started to talk about Pfizer (PFE) in this morning's Market Recon column here at Real Money and Real Money Pro. That was more about the FDA potentially authorizing Pfizer's COVID-19 vaccine for 12 to 15 year-olds rather soon, and Pfizer receiving the Biden administration's support in exporting the U.S. manufactured vaccine. That was prior to the firm's scheduled first quarter earnings release that has since occurred. With that report now in the books, let us take another look and see where the dust settled.

For Q1 2021, Pfizer reported adjusted EPS of $0.93 and GAAP EPS of $0.86, easily beating consensus by either measure. The adjusted number allows for earnings growth of 45% over the comparable period last year. Quarterly revenue generation landed at $14.6 billion, beating the street by nearly $1 billion and good for growth of 44.8%.

Businesses

Moving on to the firm's various lines of business, Vaccines has grown from $1.611 billion for Q1 2020 to $4.894 billion for Q1 2021. That's more than 300% growth but the firm for obvious reasons does not consider this line item to be comparable. The firm's second largest business, formerly the largest, is Oncology where sales grew 18% to $2.862 billion. Internal Medicine increased 11% to $2.594 billion. Hospital grew 12% to $2.343 billion. Inflammation & Immunology experienced a 9% rise to $1.065 billion, while Rare Disease saw a 29% pop to $864 million. Clearly, the entire firm is seeing increased business on a broad level. Though developing and distributing the firm's messenger RNA vaccine BNT162b2, a collaborative effort with BioNtech (BNTX) , has obviously become the firm's most high profile effort, there is visible progress everywhere.

On patents, the firm did lose patent protection for its Chantix anti-smoking medication late last year and there had been concern for Pfizer's breast cancer drug Ibrance. During the quarter reported, in February, the firm was granted an extension by the U.S. Patent and Trade Office not to expire before March of 2027.

As for other well-known drugs marketed and sold by Pfizer.... Vyndaqel/Vyndamax (heart failure) saw sales growth of 88%, while Eliquis (blood clots) experienced 25% growth, and Xeljanz (arthritis, ulcerative colitis) sales popped 18%.

Moving Forward

Pfizer expects to deliver 1.5 billion doses globally in 2021. The firm is boosting expected revenue produced by the BNT-162b2 COVID vaccine from $15 billion to $26 billion. This ups the firm's overall full year revenue guidance from $59.4 billion to $61.4 billion, all the way to $70.5 billion to $72.5 billion. Wall Street was around $61.5 billion on that number. The firm is also boosting guidance for adjusted EPS to $3.55 to $3.65 from $3.10 to $3.20. The street was pretty much in between $3.30 and $3.35 here. Revenue guidance ex-the COVID-19 vaccine reflects an increase of $200 million.

The Chart

The stock showed some life early on this morning, and has now come in a bit.

On the plus side, PFE now wrestles with breaking out past a $39 pivot. This morning, there appears to be resistance, as Relative Strength currently stands in overbought space, and the daily MACD looks as indecisive as it gets up here. That said, you can wait if you are flat (or looking to add), but should this stock push on past pivot, you only have a dollar or so of room to make that purchase before the risk/reward proposition starts working again. Keep in mind that one of the best things about Pfizer for shareholders is that this name is not volatile... not that risky... and does pay shareholders a cool $1.56 (yielding 3.9%) just to be there.

Pfizer

Target Price: $48 (reiteration)

Pivot Point: $39

Panic: $36 (up from $35)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long PFE equity.

TAGS: Drug Approvals | Earnings | Investing | Stocks | Technical Analysis | Trading | Biotechnology | Healthcare | Pharmaceuticals

More from Investing

Not Even the Mega-Cap Tech Stocks Could Hide From the Selling

James "Rev Shark" DePorre
Oct 3, 2023 4:37 PM EDT

Like or not, this is classic bear market action playing out.

McCormick Might Leave a Bad Taste in Investors' Mouths

Bruce Kamich
Oct 3, 2023 2:51 PM EDT

The charts don't look very appetizing for the spice company.

American Express: Leave Home Without It

Bruce Kamich
Oct 3, 2023 1:55 PM EDT

The charts show further declines ahead for the credit card company.

Costco: Are We Witnessing a Bull Trap?

Bruce Kamich
Oct 3, 2023 1:08 PM EDT

When one of the last holdouts of the S&P 500 turns down the selloff is in full gear.

Chasing Alpha With Alphabet

Ed Ponsi
Oct 3, 2023 12:35 PM EDT

I'm not the only one who likes the tech behemoth. Bill Ackman believes Alphabet will be a leader in AI for years to come.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login